We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
Read MoreHide Full Article
Key Takeaways
GEHC's MINItrace Magni wins CE Mark, enabling local production of four radioisotopes for PET imaging.
GEHC expands its PETtrace platform to support Copper-64 production, advancing radiopharmaceutical research.
GEHC's expanded portfolio supports molecular imaging and theranostics across emerging cancer applications.
GE HealthCare Technologies (GEHC - Free Report) recently announced that its MINItrace Magni cyclotron has received CE Mark certification, advancing the company's efforts to expand local production of radioisotopes used in positron emission tomography (PET) imaging. The company also expanded its PETtrace Solid Target Platform to support Copper-64 production, broadening its capabilities beyond Gallium-68 and Zirconium-89. These developments strengthen GE HealthCare's molecular imaging portfolio and support emerging research into radiopharmaceuticals and theranostics.
The CE Mark enables the MINItrace Magni to support in-house production of Fluorine-18, Carbon-11, Oxygen-15 and Nitrogen-13 for PET tracers. By combining a compact, self-shielded design with automated operation, the system is intended to help healthcare institutions establish or expand local radioisotope production without requiring large-scale production infrastructure.
More on the News
PET imaging depends on radioisotopes that can lose their usefulness quickly because of their short half-lives. Producing these products closer to healthcare facilities can improve supply planning, reduce dependence on external production and transportation, and provide greater flexibility in scheduling imaging procedures.
According to GE HealthCare, MINItrace Magni features an intuitive interface and a three-click workflow. Its automated functions include preparing the cyclotron and targets, tuning the radiation beam and managing target irradiation. The system can also be integrated with the company's TRACERcenter Solutions to support broader radiopharmacy workflows.
The PETtrace platform's addition of Copper-64 expands its solid-target capabilities beyond Gallium-68, introduced in 2022, and Zirconium-89, added in early 2026. Copper-64 is being investigated for PET imaging and in combination with Copper-67, a potential therapeutic counterpart that could enable a diagnostic-and-treatment approach known as theranostics. Research involving Copper-64-labeled compounds includes applications in prostate cancer and HER2-positive breast cancer. These applications remain under investigation.
Strategic Implications
The developments reflect GE HealthCare's broader strategy of connecting imaging equipment with radioisotope production and radiopharmacy infrastructure. As molecular imaging expands across oncology, neurology and cardiology, reliable isotope availability could become increasingly important for healthcare providers. The expanded platform also offers research institutions greater flexibility to explore new radiopharmaceutical applications, although commercial benefits will depend on customer adoption and the progress of clinical research.
Industry Outlook
Per a report by Precedence Research, the global radiopharmaceutical market size was valued at $7.51 billion in 2025 and is projected to grow from $8.28 billion in 2026 to $15.21 billion by 2033, at a CAGR of 7.3% from 2026 to 2033.
Demand is being driven by prostate and neuroendocrine cancer diagnosis and expansion in Asia-Pacific market. The next growth wave is likely to be driven alpha-emitting therapies, new PET tracers and earlier-line treatment expansion.
Peers in the Radiopharmaceutical Space
Other radiopharmaceutical and theranostics companies like Lantheus , Radiopharm Theranostics and Telix Pharmaceuticals (TLX - Free Report) are also developing their product portfolio to gain from the rising demand in this space.
Lantheus strengthened its radiopharmaceutical portfolio with two notable regulatory developments in the past three months. In August 2026, the FDA approved Tauklarify, a PET imaging agent designed to detect abnormal tau protein deposits in adults with cognitive impairment being evaluated for Alzheimer’s disease.
In September, the FDA granted final approval to BRAVNETSA (lutetium Lu 177 dotatate), a radioligand therapy for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Approved through the abbreviated new drug application pathway, BRAVNETSA expands treatment options and establishes a new regulatory milestone for radioligand therapies.
Radiopharm Theranostics advanced the regulatory development of its investigational imaging agent RAD101 following an End-of-Phase 2 meeting with the FDA on Oct. 5, 2026. The discussions focused on the pivotal Phase 3 trial design for detecting suspected recurrent brain metastases after radiotherapy. RAD101 had previously demonstrated 93% concordance with MRI across evaluable lesions in its Phase 2b study, meeting the primary endpoint. The company is preparing for Phase 3 development, with formal FDA meeting minutes expected to clarify the next steps.
Telix Pharmaceuticals secured two important FDA milestones in September 2026. On Sept. 14, the FDA approved Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma, helping distinguish recurrent or progressive brain tumors from treatment-related changes in adults and children aged at least one month.
On Sept. 30, Telix received Fast Track designation for its BiPASS program, which evaluates PSMA-PET imaging alongside MRI before prostate biopsy. These developments expand diagnostic applications while supporting further regulatory progress in prostate cancer imaging.
View the Zacks #1 Rank List
Image: Bigstock
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
Key Takeaways
GE HealthCare Technologies (GEHC - Free Report) recently announced that its MINItrace Magni cyclotron has received CE Mark certification, advancing the company's efforts to expand local production of radioisotopes used in positron emission tomography (PET) imaging. The company also expanded its PETtrace Solid Target Platform to support Copper-64 production, broadening its capabilities beyond Gallium-68 and Zirconium-89. These developments strengthen GE HealthCare's molecular imaging portfolio and support emerging research into radiopharmaceuticals and theranostics.
The CE Mark enables the MINItrace Magni to support in-house production of Fluorine-18, Carbon-11, Oxygen-15 and Nitrogen-13 for PET tracers. By combining a compact, self-shielded design with automated operation, the system is intended to help healthcare institutions establish or expand local radioisotope production without requiring large-scale production infrastructure.
More on the News
PET imaging depends on radioisotopes that can lose their usefulness quickly because of their short half-lives. Producing these products closer to healthcare facilities can improve supply planning, reduce dependence on external production and transportation, and provide greater flexibility in scheduling imaging procedures.
According to GE HealthCare, MINItrace Magni features an intuitive interface and a three-click workflow. Its automated functions include preparing the cyclotron and targets, tuning the radiation beam and managing target irradiation. The system can also be integrated with the company's TRACERcenter Solutions to support broader radiopharmacy workflows.
The PETtrace platform's addition of Copper-64 expands its solid-target capabilities beyond Gallium-68, introduced in 2022, and Zirconium-89, added in early 2026. Copper-64 is being investigated for PET imaging and in combination with Copper-67, a potential therapeutic counterpart that could enable a diagnostic-and-treatment approach known as theranostics. Research involving Copper-64-labeled compounds includes applications in prostate cancer and HER2-positive breast cancer. These applications remain under investigation.
Strategic Implications
The developments reflect GE HealthCare's broader strategy of connecting imaging equipment with radioisotope production and radiopharmacy infrastructure. As molecular imaging expands across oncology, neurology and cardiology, reliable isotope availability could become increasingly important for healthcare providers. The expanded platform also offers research institutions greater flexibility to explore new radiopharmaceutical applications, although commercial benefits will depend on customer adoption and the progress of clinical research.
Industry Outlook
Per a report by Precedence Research, the global radiopharmaceutical market size was valued at $7.51 billion in 2025 and is projected to grow from $8.28 billion in 2026 to $15.21 billion by 2033, at a CAGR of 7.3% from 2026 to 2033.
Demand is being driven by prostate and neuroendocrine cancer diagnosis and expansion in Asia-Pacific market. The next growth wave is likely to be driven alpha-emitting therapies, new PET tracers and earlier-line treatment expansion.
Peers in the Radiopharmaceutical Space
Other radiopharmaceutical and theranostics companies like Lantheus , Radiopharm Theranostics and Telix Pharmaceuticals (TLX - Free Report) are also developing their product portfolio to gain from the rising demand in this space.
Lantheus strengthened its radiopharmaceutical portfolio with two notable regulatory developments in the past three months. In August 2026, the FDA approved Tauklarify, a PET imaging agent designed to detect abnormal tau protein deposits in adults with cognitive impairment being evaluated for Alzheimer’s disease.
In September, the FDA granted final approval to BRAVNETSA (lutetium Lu 177 dotatate), a radioligand therapy for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Approved through the abbreviated new drug application pathway, BRAVNETSA expands treatment options and establishes a new regulatory milestone for radioligand therapies.
Radiopharm Theranostics advanced the regulatory development of its investigational imaging agent RAD101 following an End-of-Phase 2 meeting with the FDA on Oct. 5, 2026. The discussions focused on the pivotal Phase 3 trial design for detecting suspected recurrent brain metastases after radiotherapy. RAD101 had previously demonstrated 93% concordance with MRI across evaluable lesions in its Phase 2b study, meeting the primary endpoint. The company is preparing for Phase 3 development, with formal FDA meeting minutes expected to clarify the next steps.
Telix Pharmaceuticals secured two important FDA milestones in September 2026. On Sept. 14, the FDA approved Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma, helping distinguish recurrent or progressive brain tumors from treatment-related changes in adults and children aged at least one month.
On Sept. 30, Telix received Fast Track designation for its BiPASS program, which evaluates PSMA-PET imaging alongside MRI before prostate biopsy. These developments expand diagnostic applications while supporting further regulatory progress in prostate cancer imaging.